# 2026-10813: NIH Licenses New Antibody to Spot Immune Cell Proteins 2026-10813, Government-Owned Inventions; Availability for Licensing, is a Federal Register notice from Health and Human Services Department, National Institutes of Health published 2026-06-01, effective 2026-05-26; PRIA reads it as touching household money (as of 2026-06-08). - Canonical: https://policyrisk.com/federal-register/2026-10813 - As of: 2026-06-08 - Plain-text twin of the page above; the HTML and this file carry the same facts. ## Facts - Document number: 2026-10813 - Title: Government-Owned Inventions; Availability for Licensing - Type: Notice - Agencies: Health and Human Services Department; National Institutes of Health - Citation: 91 FR 32405 - Published: 2026-06-01 - Effective: 2026-05-26 - Comments close: not stated - Significant: no - Touches household money: yes - Regulation identifier numbers: none - Last updated: 2026-06-08 ## In one line NIH Licenses New Antibody to Spot Immune Cell Proteins ## Summary The National Institutes of Health just announced a cool new antibody called 18H2 that helps scientists spot a key protein in immune cells that keep us healthy. This invention is ready for companies to license and turn into real products, speeding up research and treatments for autoimmune diseases. If you’re interested, now’s the time to reach out and get the details—money and timing depend on your licensing deal! ## Abstract The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is giving notice of the invention listed below, which is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. ## Effects PRIA read - Antibody 18H2 Available For Licensing: benefit, medium. The NIH/NIAID has made monoclonal antibody 18H2 (HHS Ref. No. E-104-2025-0) available for licensing for commercial development under 35 U.S.C. 209 and 37 CFR part 404. If you are a company or research group, you can contact Yogikala Prabhu (tel. 202-365-4785 or [email protected]) to inquire about l… - Collaborative Research Opportunities Offered: benefit, medium. NIAID is actively seeking statements of capability or interest for collaborative research to further develop, evaluate, or commercialize 18H2, including use in pre-clinical models, diagnostic assay development, and high-throughput screening. Interested parties should contact Yogikala Prabhu at 202-… - Enables Development of Diagnostic Tests: benefit, medium. The 18H2 antibody can be used to develop tests that track regulatory T cell (Treg) function and Eos protein levels in patients to monitor autoimmune diseases, cancer treatments, and organ transplants. Companies and labs could use this technology to build diagnostic assays and immune-monitoring tool… - Confidential Disclosure Agreement Required: cost, low. A signed Confidential Disclosure Agreement (CDA) is required to receive copies of unpublished information related to the 18H2 invention. Parties must sign the CDA before NIH/NIAID will provide unpublished technical details. - Foreign Patent Filings May Extend Coverage: benefit, low. The notice states that foreign patent applications are filed on selected inventions to extend market coverage and may also be available for licensing. This can affect the geographic scope of licensing rights for 18H2. - Technology Is at Pre-Clinical Stage: cost, medium. The 18H2 antibody is described as being at the 'Pre-Clinical' development stage. That means the technology has been validated in laboratory settings but has not yet reached clinical trials or market-ready status. ## Related documents - [2026-20705](https://policyrisk.com/federal-register/2026-20705): Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Antibody Specifically Binding to Severe Fever With…, 2026-10-09 - [2026-20771](https://policyrisk.com/federal-register/2026-20771): Center for Scientific Review; Notice of Closed Meetings, 2026-10-09 - [2026-20424](https://policyrisk.com/federal-register/2026-20424): National Cancer Institute; Notice of Meeting, 2026-10-06 - [2026-20365](https://policyrisk.com/federal-register/2026-20365): Center For Scientific Review; Notice of Closed Meetings, 2026-10-05 - [2026-20151](https://policyrisk.com/federal-register/2026-20151): Notice of NIH Tribal Consultations and Listening Session, 2026-10-01 - [2026-19719](https://policyrisk.com/federal-register/2026-19719): Center for Scientific Review; Amended Notice of Meeting, 2026-09-28 ## Sources - [2026-10813 on federalregister.gov](https://www.federalregister.gov/documents/2026/06/01/2026-10813/government-owned-inventions-availability-for-licensing) - [2026-10813 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-06-01/pdf/2026-10813.pdf) ## Related - [Previous: 2026-10811, National Eye Institute; Notice of Closed Meeting](https://policyrisk.com/federal-register/2026-10811) - [Next: 2026-10814, Center for Scientific Review; Notice of Closed Meetings](https://policyrisk.com/federal-register/2026-10814) - [All Federal Register documents](https://policyrisk.com/federal-register) Source: PRIA, https://policyrisk.com/federal-register/2026-10813 (as of 2026-06-08).